Open AccessP687: A PHASE 1 STUDY WITH THE NOVEL B‐CELL LYMPHOMA 2 (BCL2) INHIBITOR BGB‐11417 AS MONOTHERAPY OR IN COMBINATION WITH ZANUBRUTINIB (ZANU) IN PATIENTS (PTS) WITH B‐CELL MALIGNANCIES: PRELIMINARY DATA
Author(s) -
Opat S.,
Cheah C. Y.,
Lasica M.,
Verner E.,
Browett P. J.,
Chan H.,
Soumerai J. D.,
González Barca E.,
Hilger J.,
Fang Y.,
Huang J.,
Simpson D.,
Tam C. S.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000845632.15209.07
Subject(s) - venetoclax , medicine , tolerability , lymphoma , pharmacology , chronic lymphocytic leukemia , oncology , leukemia , cancer research , adverse effect